AllantoinvsEGF (Epidermal Growth Factor)

Allantoin (5-ureidohydantoin) stimulates cell proliferation and tissue regeneration by promoting fibroblast activity, keratinocyte proliferation, and extracellular matrix synthesis including collagen and glycosaminoglycans. It acts as a mild keratolytic by promoting the natural desquamation process—loosening corneocyte adhesion and facilitating shedding—without the irritation, pH disruption, or barrier compromise associated with alpha- or beta-hydroxy acids. Allantoin has anti-inflammatory properties through modulation of prostaglandin synthesis (inhibiting COX-2 and reducing PGE2) and may downregulate pro-inflammatory cytokines. Its moisturizing effect comes from increasing the water-binding capacity of the extracellular matrix and stratum corneum; it is highly soluble and forms hydrogen bonds with water. Allantoin also promotes wound epithelialization. Its safety profile—non-irritating, non-sensitizing, non-comedogenic—makes it suitable for compromised skin, post-procedure care, and infant formulations.

EGF binds EGFR/ErbB1 on keratinocytes and fibroblasts, triggering dimerization and autophosphorylation. Activates MAPK/ERK (Ras-Raf-MEK-ERK) and PI3K/AKT pathways, promoting proliferation, migration (actin reorganization, focal adhesion turnover), and differentiation. Upregulates cyclin D1, inhibits p27. Stimulates fibroblast collagen types I/III and hyaluronic acid via HAS2. In wound healing, accelerates re-epithelialization via keratinocyte migration and reduces scarring via TGF-beta modulation. For anti-aging, promotes cellular renewal and extracellular matrix production. Theoretical cancer concern from EGFR's growth role — topical EGF has not been shown to penetrate to basal layer or systemic circulation significantly.